Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/20/2007WO2007088123A3 Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
09/20/2007WO2007087518A3 2-substituted benzimidazoles as selective androgen receptor modulators (sarms)
09/20/2007WO2007087416A3 Methods of increasing oral bioavailability of tetracyclines
09/20/2007WO2007086914A3 Nanoparticulate clopidogrel formulations
09/20/2007WO2007086082A3 A process for manufacturing rosuvastatin potassium and crystalline and amorphous forms thereof
09/20/2007WO2007085557A3 Use of substituted 2-imidazole of imidazoline derivatives
09/20/2007WO2007084560A3 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH
09/20/2007WO2007084390A3 Histone deacetylase inhibitors
09/20/2007WO2007083101A3 Use in an alternative treatment of cancer
09/20/2007WO2007082922A3 Long term treatment of hiv- infection with tcm278
09/20/2007WO2007081299A3 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
09/20/2007WO2007080270A3 New cholest-4-en-3-one oxime derivatives, pharmaceutical compositions comprising them, and preparation process
09/20/2007WO2007079715A3 Novel lysolipin derivatives
09/20/2007WO2007079198A3 Metaxalone formulations and methods for the preparation thereof
09/20/2007WO2007075964A3 Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
09/20/2007WO2007075554A3 Combination of igfr inhibitor and anti-cancer agent
09/20/2007WO2007074491A8 HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
09/20/2007WO2007071625A3 Cyclic peptides and their use in treating advanced stage neuroblastoma
09/20/2007WO2007071396A8 Pyrazinoylguanidine compounds useful in the treatment of inflammatory or allergic conditions
09/20/2007WO2007066041A3 Skin depigmentation composition containing a naphthonic acid derivative
09/20/2007WO2007063335A3 Amphotericin b salt
09/20/2007WO2007062230A3 Nuclear receptor binding agents
09/20/2007WO2007061995A3 Biomarkers for statin-induced myopathy or rhabdomyolysis
09/20/2007WO2007057756B1 Isocystene derivatives for the treatment of pain
09/20/2007WO2007056500A3 Compounds with activity at estrogen receptors
09/20/2007WO2007056075A3 Six membered heteroaromatic inhibitors targeting resistant kinase mutations
09/20/2007WO2007055804A3 Methods and compositions for administration of iron for the treatment of restless leg syndrome
09/20/2007WO2007053400A3 Piperidine glycine transporter inhibitors
09/20/2007WO2007050975A3 Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
09/20/2007WO2007050724A3 Lipophilic vehicle-based dual controlled release matrix system as capsule fill
09/20/2007WO2007047539A3 Localized delivery to the lymphatic system
09/20/2007WO2007047339A3 Methods of inhibiting poxvirus growth
09/20/2007WO2007042899B1 Human microrna targets in hiv genome and a method of identification thereof
09/20/2007WO2007041358A3 Substituted pyrazole compounds
09/20/2007WO2007036743A3 Quinolines and their therapeutic use
09/20/2007WO2007036376A3 Skincare products
09/20/2007WO2007035823A3 Partial mglur5 antagonists and methods of use thereof
09/20/2007WO2007033193A3 Sustained-release formulation comprising a glucuronate salt of a piperazine compound and uses thereof
09/20/2007WO2007030581A3 Neuroprotectants
09/20/2007WO2007024876A3 Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
09/20/2007WO2007024707A3 Tlr agonists
09/20/2007WO2007022445A3 Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
09/20/2007WO2007022443A3 Systemic and intrathecal effects of a novel series of phospholipase a2 inhibitors on hyperalgesia and spinal pge2 release
09/20/2007WO2007019184A3 Oral suspension of prednisolone acetate
09/20/2007WO2007019130A3 Hiv integrase inhibitors
09/20/2007WO2007010559A3 Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
09/20/2007WO2006138118B1 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
09/20/2007WO2006136175A3 Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
09/20/2007WO2006135406A3 Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents
09/20/2007WO2006123357A3 Oral controlled release composition containing levetiracetam
09/20/2007WO2006119736A3 Pdz-domain modulators
09/20/2007WO2006113509A3 Quinobenzoxazine analogs and methods of using thereof
09/20/2007WO2006089286A3 Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
09/20/2007WO2006084412A9 Method for purifying noroxymorphone compounds
09/20/2007WO2006084198A3 Nitroxides for use in treating or preventing immunological diseases
09/20/2007WO2006060819A3 Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
09/20/2007WO2006017384A3 Indazoles useful in treating cardiovascular diseases
09/20/2007WO2005120152A3 Cationic lipids and methods of use
09/20/2007WO2005023995A3 Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
09/20/2007WO2005019190A3 (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
09/20/2007WO2005011590A3 Compositions and methods for restoring sensitivity to treatment with her2 antagonists
09/20/2007WO2002000649A9 Substituted quinazoline derivatives and their use as inhibitors
09/20/2007US20070219552 Spine distraction implant and method
09/20/2007US20070219347 Meningitidis B serogroup; amino acid sequence encoded by nucleotides 564043 to 565882 of sequence 1; monoclonal antibodies; vaccine antigens
09/20/2007US20070219278 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus
09/20/2007US20070219277 Small molecules used to increase cell death
09/20/2007US20070219276 increased bioavailability, enhanced aqueous solubility; anticancer agents; with combination therapy using at least one texaphyrin metal complex like motexafin gadolinium; with an optionally substituted PEG group or hydroxylated group
09/20/2007US20070219275 Use of Benzophenone Uv Filters for Preventing Tanning
09/20/2007US20070219274 (R)-Chiral Halogenated Substituted Fused Heterocyclic Amino Compounds Useful for Inhibiting Cholesterol Ester Transfer Protein Activity
09/20/2007US20070219272 Novel method and compositions for treatment of tinnitus
09/20/2007US20070219271 Pharmaceutical Compositions Containing Pufa And At Least One Of An Immunosuppressive Agent Or An Antineoplastic Agent
09/20/2007US20070219270 Medium Chain Fatty Acids Applicable as Anti-Microbial Agents
09/20/2007US20070219269 Novel aconitase
09/20/2007US20070219268 Anti-cancer activity augmentation compounds and formulations and methods of use thereof
09/20/2007US20070219267 Product for treating warts
09/20/2007US20070219266 N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders
09/20/2007US20070219265 Substituted gamma lactams as therapeutic agents
09/20/2007US20070219264 inhibiting rejection of a transplanted organ, tissue or cell in a recipient mammal; immunosuppressive agent; autoimmune diseases
09/20/2007US20070219263 Metronidazole/azelaic acid compositions for the treatment of rosacea
09/20/2007US20070219262 omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists
09/20/2007US20070219261 Anthranilamide and 2-amino-heteroarene-carboxamide compounds
09/20/2007US20070219259 New 3-phenylpropionic acid derivatives
09/20/2007US20070219258 Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
09/20/2007US20070219257 Wnt Pathway Antagonists
09/20/2007US20070219256 Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
09/20/2007US20070219255 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
09/20/2007US20070219254 Therapeutic Compounds: Pyridine N-Oxide Scaffold
09/20/2007US20070219253 Decongestant / antihistaminic / expectorant compositions
09/20/2007US20070219252 Vla-R Antagonists
09/20/2007US20070219251 Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
09/20/2007US20070219250 Pharmaceutical Compositions of Nateglinide
09/20/2007US20070219249 Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof
09/20/2007US20070219248 Salt of Oxalic Acid with -[4[2-(N-Methyl-N-(2-Pyridyl)-Amino)Ethoxy]Benzyl]Thiazolidin-2,4- Dione and a Method of its Preparation and its Use
09/20/2007US20070219247 Medicament
09/20/2007US20070219246 Dihydrobenzothiophenes
09/20/2007US20070219245 Method of use for substituted dipiperidine ccr2 antagonists
09/20/2007US20070219244 Histone deacetylase inhibitors as therapeutics for neurological diseases
09/20/2007US20070219243 Method for improving the pharmacokinetics of HIV integrase inhibitors
09/20/2007US20070219242 oxoquinoline derivatives such as 4-[3-carboxyethyl-1,4-dihydro-1-(4-fluorophenyl)methyl-4-oxoquinolin-6-yl]-2,4-dioxobutanoic acid, ethyl ester, used for preventing or treating acquired immunodeficiency syndrome (AIDS) infection
09/20/2007US20070219241 Organic Compounds Useful For The Treatment Of Alzheimer's Disease, Their Use And Method Of Preparation